Group Chairman of Pharmaceutical
Research and Development,
Johnson & Johnson
Dr. Paul Stoffels is Global Head, Research & Development, Pharmaceuticals at Johnson & Johnson. He is focused on leading a global R&D organization to discover and develop new and innovative treatments for unmet medical needs in oncology, immunology, neuroscience, pain, cardiovascular, metabolism and infectious diseases.
Dr. Stoffels has 20 years global experience in both pharmaceutical and HIV/AIDS R&D. He joined Janssen and worked for four years as Physician/Researcher in Kinshasa (Congo) and Kigali (Rwanda) in the field of HIV/AIDS and infectious diseases. In 1991 he joined the ID team at Janssen in Beerse, Belgium. In 1997, he left Janssen to become CEO of Tibotec-Virco, where he transitioned the company from a technology-based research company into an integrated pharmaceutical R&D organization focused on HIV/AIDS and infectious diseases. Johnson & Johnson acquired Tibotec-Virco in 2002.
Dr. Stoffels has a special interest for the health care problems in the developing world, especially Africa, with a focus on developing a new drug for TB and simplified, effective treatment and prevention for HIV.
Dr Stoffels studied Medicine at the University of Antwerp and the Institute of Tropical Medicine in Antwerp, Belgium.
Open Innovation in Life Sciences: the only way forward to tackle unmet medical need ( 3.2MB)
Dr. Stoffels will start from the present landscape in life sciences. He will talk about the current bottle necks to get to new medicines, how to pass them by or how to bring solutions to avoid them.
He will make some proposals to get to a long term sustainable model that is beneficial for society, patients, academia, biotech and big industry.